Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1
Authors:
- H. SprottHSH. Sprott
- M. GlatzelMGM. Glatzel
- B. A. MichelBMB. A. Michel
Open Access
- 1 April 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 43 (4) , 524-526
Abstract
Sir, Polymyositis is an inflammatory myopathy that is related to progressive, proximal, symmetrical muscle weakness, increased concentrations of serum muscle enzymes, an abnormal electromyogram and an abnormal muscle biopsy showing inflammation. Standard drug therapy includes high-dose corticosteroids and immunosuppressive drugs (methotrexate, azathioprine or even cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immune-modulating drug in addition to corticosteroid therapy. In patients with corticosteroid- and immunosuppressive-resistant myositis, management approaches include intravenous high-dose pulse methylprednisolone combined with immunosuppressive drugs, and combination therapy with methotrexate and azathioprine, cyclosporin and/or intravenous immunoglobulin (Ig). Lack of efficacy occurs in some cases. Recent advances in the understanding of the role of cytokines and complement in the pathogenesis of myositis have led to preliminary therapeutic trials of biological agents: etanercept, infliximab and anti-C5 monoclonal antibody [1].Keywords
This publication has 5 references indexed in Scilit:
- Periodic fever due to a novel TNFRSF1A mutation in a heterozygous Chinese carrier of MEFV E148QRheumatology, 2004
- Recent advances in the management of adult myositisExpert Opinion on Investigational Drugs, 2001
- TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanerceptExpert Opinion on Pharmacotherapy, 2001
- Elevation of Serum Soluble Tumour Necrosis Factor Receptors in Patients with Polymyositis and DermatomyositisClinical Rheumatology, 2000
- Clinical experience with soluble TNF p75 receptor in rheumatoid arthritisSeminars in Arthritis and Rheumatism, 1999